Novartis (NOVN) Given a CHF 110 Price Target by Goldman Sachs Group Analysts
Novartis (VTX:NOVN) has been assigned a CHF 110 target price by stock analysts at Goldman Sachs Group in a note issued to investors on Monday. The firm presently has a “buy” rating on the stock. Goldman Sachs Group’s price target indicates a potential upside of 40.34% from the stock’s current price.
A number of other brokerages have also recently issued reports on NOVN. Deutsche Bank set a CHF 89 target price on shares of Novartis and gave the company a “neutral” rating in a report on Friday, September 28th. UBS Group set a CHF 82 price target on shares of Novartis and gave the stock a “neutral” rating in a report on Tuesday, September 25th. Baader Bank set a CHF 89 price target on shares of Novartis and gave the stock a “buy” rating in a report on Friday, October 12th. JPMorgan Chase & Co. set a CHF 87 price target on shares of Novartis and gave the stock a “neutral” rating in a report on Tuesday, October 16th. Finally, HSBC set a CHF 84 price target on shares of Novartis and gave the stock a “neutral” rating in a report on Thursday, October 25th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Novartis presently has an average rating of “Buy” and a consensus price target of CHF 90.60.
Shares of NOVN stock opened at CHF 78.38 on Monday. Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
See Also: Trading Strategy
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.